Kiniksa Pharmaceuticals International (KNSA) Capital Expenditures (2017 - 2026)

Kiniksa Pharmaceuticals International has reported Capital Expenditures for 10 years, with the latest figure at $108000.0 in Q1 2026.

• For the quarter ending Q1 2026, Capital Expenditures rose 217.65% year-over-year to $108000.0; the trailing twelve-month figure through Mar 2026 stood at $157000.0 (up 84.71% YoY), and the FY2025 full-year result was $83000.0, down 45.75% from the prior year.
• Capital Expenditures for Q1 2026 stood at $108000.0, up from -$852000.0 in the prior quarter.
• The five-year high for Capital Expenditures was $597000.0 in Q3 2025, with the low at -$852000.0 in Q4 2025.
• Historically, Capital Expenditures has averaged $33142.9 across 5 years, with a median of $34000.0 in 2023.
• The largest YoY upside for Capital Expenditures was 1788.89% in 2025 against a maximum downside of 1334.78% in 2025.
• Kiniksa Pharmaceuticals International's Capital Expenditures stood at -$32000.0 in 2022, then surged by 275.0% to $56000.0 in 2023, then increased by 23.21% to $69000.0 in 2024, then tumbled by 1334.78% to -$852000.0 in 2025, then soared by 112.68% to $108000.0 in 2026.
• The last three Capital Expenditures figures came in at $108000.0 (Q1 2026), -$852000.0 (Q4 2025), and $597000.0 (Q3 2025), per Business Quant data.